hh-120
Recombinant proteinexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05116865)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05787418 | Phase 3 | Mar 31, 2023 | Huahui Health |
| NCT05713318 | Phase 2 | Jan 18, 2023 | Huahui Health |
| NCT05753878 | Phase 1 | Nov 8, 2022 | Huahui Health |
| NCT05765279 | N/A | Oct 20, 2022 | Capital Medical University |
| NCT05659602 | N/A | Jul 9, 2022 | Capital Medical University |
| NCT05747677 | N/A | Jun 14, 2022 | Capital Medical University |
| NCT06039163 | Phase 1 | Apr 16, 2022 | Huahui Health |
| NCT05116865 | Phase 1 | Nov 30, 2021 | Huahui Health |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huahui Health | Academic/Hospital | 5 | 5 | 3 | 2021 |
| Capital Medical University | Academic/Hospital | 3 | 3 | 1 | 2022 |
2 organizations
Page 1 / 1